BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $57.09.
Several research analysts have commented on BBIO shares. Wall Street Zen upgraded BridgeBio Pharma from a "sell" rating to a "hold" rating in a report on Saturday. Cantor Fitzgerald restated an "overweight" rating and set a $95.00 price objective on shares of BridgeBio Pharma in a report on Friday, February 21st. Redburn Atlantic started coverage on BridgeBio Pharma in a report on Monday, March 31st. They set a "buy" rating and a $50.00 price objective on the stock. Citigroup raised their price objective on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Finally, HC Wainwright raised their price objective on BridgeBio Pharma from $49.00 to $53.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th.
Get Our Latest Report on BBIO
Insider Activity
In related news, CAO Maricel Apuli sold 1,026 shares of the business's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $38.51, for a total transaction of $39,511.26. Following the transaction, the chief accounting officer now directly owns 147,639 shares in the company, valued at $5,685,577.89. The trade was a 0.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Neil Kumar sold 75,000 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $36.87, for a total value of $2,765,250.00. Following the transaction, the chief executive officer now owns 4,948,447 shares in the company, valued at approximately $182,449,240.89. This trade represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 6,392,182 shares of company stock worth $219,161,291. 18.20% of the stock is currently owned by company insiders.
Institutional Trading of BridgeBio Pharma
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC lifted its position in BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after acquiring an additional 472 shares during the period. GAMMA Investing LLC lifted its position in BridgeBio Pharma by 71.0% during the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after acquiring an additional 382 shares during the period. Jones Financial Companies Lllp acquired a new stake in BridgeBio Pharma during the 1st quarter worth about $35,000. Itau Unibanco Holding S.A. acquired a new stake in BridgeBio Pharma during the 4th quarter worth about $41,000. Finally, Sterling Capital Management LLC lifted its position in BridgeBio Pharma by 554.6% during the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after acquiring an additional 1,514 shares during the period. Institutional investors and hedge funds own 99.85% of the company's stock.
BridgeBio Pharma Trading Up 0.7%
Shares of BBIO stock traded up $0.28 on Thursday, reaching $38.62. 2,682,485 shares of the company's stock were exchanged, compared to its average volume of 2,470,329. BridgeBio Pharma has a 52 week low of $21.62 and a 52 week high of $39.67. The stock has a market capitalization of $7.33 billion, a PE ratio of -13.55 and a beta of 1.10. The company's fifty day simple moving average is $34.55 and its 200 day simple moving average is $32.71.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.00) by $0.12. The business had revenue of $36.74 million for the quarter, compared to the consensus estimate of $57.14 million. During the same period in the prior year, the business posted ($0.20) earnings per share. BridgeBio Pharma's revenue was down 44.8% on a year-over-year basis. As a group, sell-side analysts predict that BridgeBio Pharma will post -3.67 earnings per share for the current fiscal year.
BridgeBio Pharma Company Profile
(
Get Free ReportBridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
See Also

Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.